Inovalis Real Estate Investment Trust
IVREF
$0.665
$0.0335.22%
| Weiss Ratings | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.13 | |||
| Price History | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | -2.49% | |||
| 90-Day Total Return | 22.02% | |||
| Year to Date Total Return | -0.39% | |||
| 1-Year Total Return | -29.26% | |||
| 2-Year Total Return | -82.77% | |||
| 3-Year Total Return | -112.83% | |||
| 5-Year Total Return | -125.34% | |||
| 52-Week High % Change | -36.06% | |||
| 52-Week Low % Change | 22.02% | |||
| Price | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.04 | |||
| 52-Week Low Price | $0.55 | |||
| 52-Week Low Price (Date) | Nov 19, 2024 | |||
| 52-Week High Price (Date) | Aug 12, 2024 | |||
| Valuation | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 20.65M | |||
| Enterprise Value | 167.17M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.77 | |||
| Earnings Per Share Growth | 124.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.78 | |||
| Price/Book (Q) | 0.14 | |||
| Enterprise Value/Revenue (TTM) | 22.10 | |||
| Price | $0.67 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -31.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 32.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $0.03 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -4.28% | |||
| Dividend Per Share (Most Recent) | $0.03 | |||
| Company Info | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 647 775 8431 | |||
| Address | 151 Yonge Street Toronto, ON M5C 2W7 | |||
| Website | www.inovalisreit.com | |||
| Country | Canada | |||
| Year Founded | 2013 | |||
| Profitability | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -69.59% | |||
| Profit Margin | -742.29% | |||
| Management Effectiveness | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -0.94% | |||
| Return on Equity | -- | |||
| Income Statement | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 13.36M | |||
| Total Revenue (TTM) | 7.79M | |||
| Revenue Per Share | $0.24 | |||
| Gross Profit (TTM) | -735.30K | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -5.42M | |||
| Net Income (TTM) | -57.84M | |||
| Net Income Avl. to Common (TTM) | -57.84M | |||
| Total Revenue Growth (Q YOY) | -21.15% | |||
| Earnings Growth (Q YOY) | -816.23% | |||
| EPS Diluted (TTM) | -1.77 | |||
| EPS Diluted Growth (Q YOY) | -835.42% | |||
| Balance Sheet | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.30M | |||
| Cash Per Share (Q) | $0.16 | |||
| Total Current Assets (Q) | 37.03M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 155.76M | |||
| Current Ratio (Q) | 0.590 | |||
| Book Value Per Share (Q) | $4.76 | |||
| Total Assets (Q) | 333.38M | |||
| Total Current Liabilities (Q) | 62.79M | |||
| Total Debt (Q) | 162.94M | |||
| Total Liabilities (Q) | 177.61M | |||
| Total Common Equity (Q) | 155.42M | |||
| Cash Flow | IVREF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 2.03M | |||
| Cash from Financing (TTM) | -8.39M | |||
| Net Change in Cash (TTM) | -9.17M | |||
| Levered Free Cash Flow (TTM) | -27.37M | |||
| Cash from Operations (TTM) | -3.63M | |||
